TY - JOUR
T1 - Reduction of Pressure Pain Sensitivity as Novel Non-pharmacological Therapeutic Approach to Type 2 Diabetes
T2 - A Randomized Trial
AU - Faber, Jens
AU - Eldrup, Ebbe
AU - Selmer, Christian
AU - Pichat, Caroline
AU - Hecquet, Sofie Korsgaard
AU - Watt, Torquil
AU - Kreiner, Svend
AU - Karpatschof, Benny
AU - Gyntelberg, Finn
AU - Ballegaard, Søren
AU - Gjedde, Albert
N1 - Funding Information:
This work was supported by the Johan Schrøders Erhvervs-og Familiefond, and Innovation Fund Denmark (Grant Reg. No: 8062-00554B).
Funding Information:
We are thankful to the staff of the Metabolic Ward O4 at Department of Medicine, Endocrine Unit, Herlev and Gentofte Hospital, for their very valuable contribution concerning the practical issues: Louise Holmberg Storck, Ulla Kjaerulff-Hansen, Marianne S?rensen, Helle R. Christensen, and Syela Azemovski; statistician Tobias Wirenfeldt Klausen for performing the statistical analyses. We also thank Christian Erik Ballegaard for research assistance. Funding. This work was supported by the Johan Schr?ders Erhvervs-og Familiefond, and Innovation Fund Denmark (Grant Reg. No: 8062-00554B).
Publisher Copyright:
© Copyright © 2021 Faber, Eldrup, Selmer, Pichat, Hecquet, Watt, Kreiner, Karpatschof, Gyntelberg, Ballegaard and Gjedde.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/3/11
Y1 - 2021/3/11
N2 - Background: Autonomic nervous system dysfunction (ANSD) is known to affect glucose metabolism in the mammalian body. Tradition holds that glucose homeostasis is regulated by the peripheral nervous system, and contemporary therapeutic intervention reflects this convention.Objectives: The present study tested the role of cerebral regulation of ANSD as consequence of novel understanding of glucose metabolism and treatment target in type 2 diabetes (T2D), suggested by the claim that the pressure pain sensitivity (PPS) of the chest bone periosteum may be a measure of cerebral ANSD.Design: In a randomized controlled trial of 144 patients with T2D, we tested the claim that 6 months of this treatment would reduce PPS and improve peripheral glucose metabolism.Results: In the active treatment group, mean glycated hemoglobin A1c (HbA1c) declined from 53.8 to 50.5 mmol/mol (intragroup p = 0.001), compared with the change from 53.8 to 53.4 mmol/mol in the control group, with the same level of diabetes treatment but not receiving the active treatment (between group p = 0.036). Mean PPS declined from 76.6 to 56.1 units (p < 0.001) in the active treatment group and from 77.5 to 72.8 units (p = 0.02; between group p < 0.001) in the control group. Changes of PPS and HbA1c were correlated (r = 0.37; p < 0.001).Conclusion: We conclude that the proposed approach to treatment of T2D is a potential supplement to conventional therapy.Clinical Trial Registration: www.clinicaltrials.gov (NCT03576430).
AB - Background: Autonomic nervous system dysfunction (ANSD) is known to affect glucose metabolism in the mammalian body. Tradition holds that glucose homeostasis is regulated by the peripheral nervous system, and contemporary therapeutic intervention reflects this convention.Objectives: The present study tested the role of cerebral regulation of ANSD as consequence of novel understanding of glucose metabolism and treatment target in type 2 diabetes (T2D), suggested by the claim that the pressure pain sensitivity (PPS) of the chest bone periosteum may be a measure of cerebral ANSD.Design: In a randomized controlled trial of 144 patients with T2D, we tested the claim that 6 months of this treatment would reduce PPS and improve peripheral glucose metabolism.Results: In the active treatment group, mean glycated hemoglobin A1c (HbA1c) declined from 53.8 to 50.5 mmol/mol (intragroup p = 0.001), compared with the change from 53.8 to 53.4 mmol/mol in the control group, with the same level of diabetes treatment but not receiving the active treatment (between group p = 0.036). Mean PPS declined from 76.6 to 56.1 units (p < 0.001) in the active treatment group and from 77.5 to 72.8 units (p = 0.02; between group p < 0.001) in the control group. Changes of PPS and HbA1c were correlated (r = 0.37; p < 0.001).Conclusion: We conclude that the proposed approach to treatment of T2D is a potential supplement to conventional therapy.Clinical Trial Registration: www.clinicaltrials.gov (NCT03576430).
KW - autonomic dysfunction
KW - glucose control
KW - glucose homeostasis
KW - HbA1c
KW - lateral hypothalamus
KW - non-pharmacological intervention
KW - pressure pain sensitivity
KW - type 2 diabetes
UR - https://www.scopus.com/pages/publications/85103329240
U2 - 10.3389/fnins.2021.613858
DO - 10.3389/fnins.2021.613858
M3 - Journal article
C2 - 33776633
AN - SCOPUS:85103329240
SN - 1662-4548
VL - 15
JO - Frontiers in Neuroscience
JF - Frontiers in Neuroscience
M1 - 613858
ER -